Cipla launches generic drug Sofosbuvir in India

25 Mar 2015 Evaluate

Cipla has launched generic drug Sofosbuvir in India under the brand name ‘Hepcvir’. Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, the company is now all set to make the drug Sofosbuvir available to Indian patients in a week’s time.

Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for hepatitis C treatment and represents a paradigm shift in the existing hepatitis C management. The high potency, high barrier to resistance, pangenotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of sofosbuvir makes it a breakthrough drug in hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90%.

Globally, it is estimated that 170-185 million people (about 3% of the world's population) are chronically infected with hepatitis C virus (HCV). Untreated chronic hepatitis C increases the risk of cirrhosis of liver, liver failure and hepatocellular carcinoma.2 In India alone, it is estimated that 12-18 million patients are infected with Hepatitis C which is several fold greater than those with HIV/AIDS. Globally, HCV is implicated in 28% of cases of liver cirrhosis and 26% of cases of hepatocellular carcinoma, which accounts for almost 500,000 deaths per year.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×